These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 14671509)

  • 1. Alternative dosing for PPI therapy: rationale and options.
    Johnson DA
    Rev Gastroenterol Disord; 2003; 3 Suppl 4():S10-5. PubMed ID: 14671509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: acid-related disease--what are the unmet clinical needs?
    Katz PO; Scheiman JM; Barkun AN
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():9-22. PubMed ID: 16700899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
    Miner PB; McKean LA; Gibb RD; Erasala GN; Ramsey DL; McRorie JW
    Aliment Pharmacol Ther; 2010 Apr; 31(8):846-51. PubMed ID: 20146702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous proton pump inhibitor therapy: a rationale for use.
    Armstrong D
    Rev Gastroenterol Disord; 2005; 5 Suppl 2():S18-30. PubMed ID: 16369224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Place and significance of proton pump inhibitors in current treatment of peptic ulcers].
    Maev IV
    Eksp Klin Gastroenterol; 2003; (3):12-13. PubMed ID: 14989296
    [No Abstract]   [Full Text] [Related]  

  • 7. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD).
    Milkes D; Gerson LB; Triadafilopoulos G
    Am J Gastroenterol; 2004 Jun; 99(6):991-6. PubMed ID: 15180715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
    Omari TI; Haslam RR; Lundborg P; Davidson GP
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):41-4. PubMed ID: 17204951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?
    Armstrong D
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():19-26; discussion 38-9. PubMed ID: 15456460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Is the successful eradication of Helicobacter pylori sufficient for the healing of peptic ulcer?].
    Pregun I; Herszényi L; Juhász M; Miheller P; Tulassay Z
    Orv Hetil; 2006 Mar; 147(10):435-9. PubMed ID: 16573172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton pump inhibitor formulary considerations in the acutely ill. Part 2: Clinical efficacy, safety, and economics.
    Devlin JW; Welage LS; Olsen KM
    Ann Pharmacother; 2005 Nov; 39(11):1844-51. PubMed ID: 16204393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial.
    Björnsson E; Abrahamsson H; Simrén M; Mattsson N; Jensen C; Agerforz P; Kilander A
    Aliment Pharmacol Ther; 2006 Sep; 24(6):945-54. PubMed ID: 16948806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: immediate-release proton-pump inhibitor therapy--potential advantages.
    Howden CW
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():25-30. PubMed ID: 16303034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic and cost effectiveness of proton pump inhibitor regimens for idiopathic or drug-induced peptic ulcer complication.
    Nam DH; Park SY; Park JM; Kim SC
    Arch Pharm Res; 2011 Mar; 34(3):443-9. PubMed ID: 21547676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
    Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-prescription of alginate based formulations & proton pump inhibitors (PPIs) in gastro-oesophageal reflux disease: time for rethink?
    Davis S; Kshirsagar NA
    Indian J Med Res; 2006 Apr; 123(4):493-6. PubMed ID: 16783039
    [No Abstract]   [Full Text] [Related]  

  • 18. Review article: putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure.
    Katz PO
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():31-8. PubMed ID: 16303035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management strategies for gastroesophageal reflux disease.
    Bak YT
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S49-53. PubMed ID: 15324382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
    Andersson K; Carlsson E
    Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.